perindoprilat has been researched along with Alloxan Diabetes in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bemelmans, M; Boudier, HS; Crijns, F; Huijberts, M; Kruseman, AN; Smits, J; Van Essen, H; Wolffenbuttel, B | 1 |
1 other study(ies) available for perindoprilat and Alloxan Diabetes
| Article | Year |
|---|---|
Inhibition of angiotensin-converting enzyme reduces urinary albumin excretion but not regional albumin clearance in experimental diabetes.
Topics: Albumins; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Capillary Permeability; Diabetes Mellitus, Experimental; Hydralazine; Indoles; Male; Random Allocation; Rats; Rats, Wistar | 1993 |